Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine.

Bachas C, Schuurhuis GJ, Hollink IH, Kwidama ZJ, Goemans BF, Zwaan CM, van den Heuvel-Eibrink MM, de Bont ES, Reinhardt D, Creutzig U, de Haas V, Assaraf YG, Kaspers GJ, Cloos J.

Blood. 2010 Oct 14;116(15):2752-8. doi: 10.1182/blood-2010-03-276519. Epub 2010 Jun 30.

PMID:
20592250
2.

FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657.

Goemans BF, Zwaan CM, Cloos J, de Lange D, Loonen AH, Reinhardt D, Hählen K, Gibson BE, Creutzig U, Kaspers GJ.

Leuk Res. 2010 Oct;34(10):1302-7. doi: 10.1016/j.leukres.2010.04.004. Epub 2010 May 1.

PMID:
20435347
3.

Outcome for children with relapsed acute myeloid leukemia in the Netherlands following initial treatment between 1980 and 1998: survival after chemotherapy only?

Goemans BF, Tamminga RY, Corbijn CM, Hählen K, Kaspers GJ.

Haematologica. 2008 Sep;93(9):1418-20. doi: 10.3324/haematol.12807. No abstract available.

4.

Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia.

Goemans BF, Zwaan CM, Vijverberg SJ, Loonen AH, Creutzig U, Hählen K, Reinhardt D, Gibson BE, Cloos J, Kaspers GJ.

Leukemia. 2008 Dec;22(12):2284-5. doi: 10.1038/leu.2008.147. Epub 2008 Jun 19. No abstract available.

PMID:
18563175
5.

Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia.

de Jonge HJ, Weidenaar AC, Ter Elst A, Boezen HM, Scherpen FJ, Bouma-Ter Steege JC, Kaspers GJ, Goemans BF, Creutzig U, Zimmermann M, Kamps WA, de Bont ES.

Clin Cancer Res. 2008 Feb 1;14(3):924-30. doi: 10.1158/1078-0432.CCR-07-1821.

6.

A comparison of the in vitro cytotoxicity of daunorubicin and liposomal daunorubicin in pediatric acute leukemia.

Goemans BF, Zwaan CM, Reinhardt D, Gibson BE, Hählen K, Kaspers GJ.

Haematologica. 2006 Nov;91(11):1573-4. Epub 2006 Oct 17.

7.

Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples.

Cloos J, Goemans BF, Hess CJ, van Oostveen JW, Waisfisz Q, Corthals S, de Lange D, Boeckx N, Hählen K, Reinhardt D, Creutzig U, Schuurhuis GJ, Zwaan ChM, Kaspers GJ.

Leukemia. 2006 Jul;20(7):1217-20. Epub 2006 Apr 27.

PMID:
16642044
8.

Differences in the prevalence of PTPN11 mutations in FAB M5 paediatric acute myeloid leukaemia.

Goemans BF, Zwaan CM, Martinelli S, Harrell P, de Lange D, Carta C, Reinhardt D, Hählen K, Creutzig U, Tartaglia M, Heinrich MC, Kaspers GJ.

Br J Haematol. 2005 Sep;130(5):801-3. No abstract available.

PMID:
16115145
9.

In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets.

Goemans BF, Zwaan CM, Harlow A, Loonen AH, Gibson BE, Hählen K, Reinhardt D, Creutzig U, Heinrich MC, Kaspers GJ.

Blood. 2005 Nov 15;106(10):3532-7. Epub 2005 Jul 28.

PMID:
16051737
10.

Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.

Goemans BF, Zwaan CM, Miller M, Zimmermann M, Harlow A, Meshinchi S, Loonen AH, Hählen K, Reinhardt D, Creutzig U, Kaspers GJ, Heinrich MC.

Leukemia. 2005 Sep;19(9):1536-42.

PMID:
16015387

Supplemental Content

Loading ...
Support Center